1. Cellphire Completes Enrollment of Phase 1 Clinical Trial of Thrombosomes®

    ROCKVILLE, Md. (July 18, 2019) – Cellphire, Inc., the global leader in long-term cell stabilization and storage of platelets and other cells, announced today that the company completed enrollment of its Phase 1 clinical trial to evaluate Thrombosomes® in bleeding, thrombocytopenic patients. Thrombosomes is a freeze-dried hemostatic agent derived from human platelets.“The success in completing […]


  2. John B. Holcomb, M.D., F.A.C.S., Joins Cellphire as Medical Consultant

    May 15, 2019 – Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that John B. Holcomb, M.D., F.A.C.S., will serve as Medical Consultant.Dr. Holcomb has extensive experience in the treatment of military and civilian trauma patients and has led three major trauma clinical trials in the […]


  3. Cellphire Awarded Subaward for DARPA Biostasis Program

    February 27, 2019 — Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that the Defense Advanced Research and Development Authority (DARPA) has awarded the company a seven-figure contract in conjunction with the University of North Carolina at Chapel Hill for Research Aimed to Extend the Golden […]


  4. Keith A. Moskowitz joins Cellphire as Vice President for Discovery

    May 1, 2018 — Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that Keith A. Moskowitz, Ph.D. MPM, has joined the company as Vice President of Discovery.  Dr. Moskowitz has more than two decades of leadership experience directing R&D, liaison and strategy in companies with revenues […]


  5. Dr. Heather F. Pidcoke joins Cellphire, Inc. as Chief Medical Officer

    March 1, 2018 — Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that Heather Pidcoke, MD, MSCI, Ph.D., has joined the company as Chief Medical Officer.  Dr. Pidcoke’s translational research interests include trauma critical care and novel transfusion products aimed at improving the resuscitation of massively […]


  6. BodeVet – Elephant Disease Causes Death by Hemorrhage… Lyophilized Platelets May Help

    February 1, 2018 — Cellphire, Inc., the global leader in long-term stabilization and storage of platelets and other cells, announced today that the in-human care population of elephants is plagued by an endotheliotropic herpes virus that attacks young elephants and causes an acute loss of platelets with associated bleeding.  BodeVet, Inc. working with the Smithsonian […]


  7. Cellphire Investors Again Receive 50% Maryland Biotechnology Investment Incentive Tax Credit

    Cellphire, Inc. announced today that investors who participated in the $3,000,000 Cellphire funding round that closed in June have received their Final Tax Credit Certificates from the Maryland Department of Commerce awarding them a 50% refundable tax credit for their investments in Cellphire.  They are now able to claim the tax refund by filing their […]


  8. BodeVet Chief Technical Officer to Present at IVECCS 2017

    BodeVet Chief Technical Officer, Anne Hale, CVM, will advise on controversies in blood banking at the International Veterinary Emergency and Critical Care Symposium, (IVECCS) 2017 in Nashville, Tennessee.  As a recognized world leader in veterinary blood banking, Dr. Hale joins a select panel of experts for a discussion of veterinary blood banking challenges.  This discussion […]


  9. Cellphire Awarded Grant to Develop Elephant Endotheliotropic Herpesvirus (EEHV) Freeze Platelet Treatment

    Thanks to a grant from the International Elephant Foundation, Cellphire, Smithsonian Global Health Program, Ringling Bros. Center for Elephant Conservation, Fort Worth Zoo and Houston Zoo have made great strides in developing a novel treatment for a lethal virus afflicting baby Asian elephants around the globe.  Elephant Endotheliotropic Herpesvirus (EEHV) is the leading cause of […]


  10. Cellphire Therapeutics Closes $3,000,000 Funding Round

    Cellphire, Inc. announced today that it had closed a $3,000,000 funding round, with investments from both new investors and existing investors, management and the board of directors.  “The additional capital will augment the $69 million commitment from BARDA [the Biomedical Advanced Research and Development Authority],” said CEO Stephen Willard, “and enables us to initiate the […]